Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 3416Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

PHARMACOVIGILANCE

Causality assessment: A brief insight into practices in pharmaceutical industry

Naidu R Purushotham

Year : 2013| Volume: 4| Issue : 4 | Page no: 233-236

   This article has been cited by
 
1 Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System
Ji Sun,Xuanyu Deng,Xiaoping Chen,Juanjuan Huang,Siqiong Huang,Yanfei Li,Jinhui Feng,Jiyang Liu,Gefei He
Clinical Pharmacology & Therapeutics. 2020;
[Pubmed]  [Google Scholar] [DOI]
2 Oxacillin-induced leukocytoclastic vasculitis
Meric Mericliler,Andrew Moraco
IDCases. 2019; : e00539
[Pubmed]  [Google Scholar] [DOI]
3 Complementing Observational Signals with Literature-Derived Distributed Representations for Post-Marketing Drug Surveillance
Justin Mower,Trevor Cohen,Devika Subramanian
Drug Safety. 2019;
[Pubmed]  [Google Scholar] [DOI]
4 Learning predictive models of drug side-effect relationships from distributed representations of literature-derived semantic predications
Justin Mower,Devika Subramanian,Trevor Cohen
Journal of the American Medical Informatics Association. 2018;
[Pubmed]  [Google Scholar] [DOI]
5 Comparison of different methods for causality assessment of adverse drug reactions
Sapan Kumar Behera,Saibal Das,Alphienes Stanley Xavier,Srinivas Velupula,Selvarajan Sandhiya
International Journal of Clinical Pharmacy. 2018;
[Pubmed]  [Google Scholar] [DOI]
6 Severe skin rash associated with efavirenz and atazanavir: a case report in a rural health facility in Kenya
K. Irungu
Drugs & Therapy Perspectives. 2018;
[Pubmed]  [Google Scholar] [DOI]
7 Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy
Bushra Weidenbusch,Günther H.S. Richter,Marie Sophie Kesper,Monika Guggemoos,Katja Gall,Carolin Prexler,Ilya Kazantsev,Alexandra Sipol,Lars Lindner,Michaela Nathrath,Olaf Witt,Katja Specht,Frigga Beitinger,Carolin Knebel,Stuart Hosie,Rüdiger von Eisenhardt-Rothe,Wilko Weichert,Irene Teichert-von Luettichau,Stefan Burdach
Oncotarget. 2018; 9(29): 20747
[Pubmed]  [Google Scholar] [DOI]
8 Adverse drug reactions in high-risk pregnant women: A prospective study
Alfredo Dias de Oliveira-Filho,Antonio Emanuel Soares Vieira,Roberta Cruz da Silva,Sabrina Joany Felizardo Neves,Thiago Antonio Barros Gama,Ryane Vieira Lima,Wlisses Ramon Oliveira,Júlia Maria de Gonçalves Dias
Saudi Pharmaceutical Journal. 2017;
[Pubmed]  [Google Scholar] [DOI]
9 Comparing Methods for Estimating Direct Costs of Adverse Drug Events
Hanna Gyllensten,Anna K. Jönsson,Katja M. Hakkarainen,Staffan Svensson,Staffan Hägg,Clas Rehnberg
Value in Health. 2017;
[Pubmed]  [Google Scholar] [DOI]
10 Polyarteritis nodosa. Diagnostic challenges in a patient with cutaneous vasculitis, psoriasis, psoriatic arthritis and pancytopenia: fatal progression after treatment with G-CSF
Paresh Jobanputra
Oxford Medical Case Reports. 2016; 2016(4): 86
[Pubmed]  [Google Scholar] [DOI]
11 Household medical waste disposal policy in Israel
Zohar Barnett-Itzhaki,Tamar Berman,Itamar Grotto,Eyal Schwartzberg
Israel Journal of Health Policy Research. 2016; 5(1)
[Pubmed]  [Google Scholar] [DOI]
12 Safety reporting through a comprehensive and pragmatic pharmcovigilance process for India and emerging markets: an industry perspective
Shashidhar Swamy,Meenakshi Mourya,Ganesh Kadhe,Amey Mane,Sandesh Sawant
Expert Opinion on Drug Safety. 2015; 14(9): 1409
[Pubmed]  [Google Scholar] [DOI]
13 Adverse drug reactions in neonates: could we be documenting more?
Daniel B Hawcutt,Olya O’Connor,Mark A Turner
Expert Review of Clinical Pharmacology. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]

 

Read this article